Literature DB >> 16931138

Coexistence of the K65R/L74V and/or K65R/T215Y mutations on the same HIV-1 genome.

Mireille Henry1, Christian Tourres, Philippe Colson, Isabelle Ravaux, Isabelle Poizot-Martin, Catherine Tamalet.   

Abstract

OBJECTIVE: To determine to which extent the mutations K65R, L74V/I and T215Y/F are linked to the same HIV-1 genome.
METHODS: Retrospective analysis of the Marseille database (8866 sequences from 3720 patients). The HIV-1 pol gene from four patients' viruses harbouring the double mutant (pure species or genotypic mixtures) was amplified, cloned and sequenced.
RESULTS: The four patients had a mean viral load of 5.6 log(10)copies/ml. Analysis of 73 clones (patient 1: 12 clones; patient 2: 27 clones; patient 3: 13 clones; patient 4: 21 clones) showed that 29 clones harboured K65R and L74V/I mutations. Twenty-three per cent of clones from the two bulk sequences harbouring K65K/R and T215T/Y genotypic mixtures contained K65R and T215Y on the same viral genome.
CONCLUSIONS: The co-linearity of 65R and 74V or 65R and 215Y amino-acids on the same genome is rare. A high viral load (6.19 log(10)) associated with the coexistence of 65R and 74V on the same HIV-1 genome suggests possible compensatory mechanisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16931138     DOI: 10.1016/j.jcv.2006.07.001

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  6 in total

1.  4'-C-methyl-2'-deoxyadenosine and 4'-C-ethyl-2'-deoxyadenosine inhibit HIV-1 replication.

Authors:  B Christie Vu; Paul L Boyer; Maqbool A Siddiqui; Victor E Marquez; Stephen H Hughes
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

2.  Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.

Authors:  Vinod Trivedi; Jana Von Lindern; Miguel Montes-Walters; Daniel R Rojo; Elisabeth J Shell; Neil Parkin; William A O'Brien; Monique R Ferguson
Journal:  AIDS Res Hum Retroviruses       Date:  2008-10       Impact factor: 2.205

3.  Hepatitis B and E co-primary infections in an HIV-1-infected patient.

Authors:  Yanis Bouamra; Souad Benali; Hervé Tissot-Dupont; Catherine Tamalet; Philippe Colson
Journal:  J Clin Microbiol       Date:  2013-01-09       Impact factor: 5.948

4.  Comparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V.

Authors:  Prem L Sharma; James H Nettles; Anya Feldman; Kimberly Rapp; Raymond F Schinazi
Journal:  Antiviral Res       Date:  2009-06-23       Impact factor: 5.970

5.  A Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus.

Authors:  Himabindu Chunduri; David Rimland; Viktoria Nurpeisov; Clyde S Crumpacker; Prem L Sharma
Journal:  Virol J       Date:  2011-01-21       Impact factor: 4.099

6.  Harnessing pharmacogenomics to tackle resistance to the "nucleoside reverse trancripatse inhibitor" backbone of highly active antiretroviral therapy in resource limited settings.

Authors:  Misaki Wayengera; Henry Kajumbula; Wilson Byarugaba
Journal:  Open AIDS J       Date:  2008-11-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.